Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites-Reference-Cited by-同舟云学术

Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites

Published:2015-08-09 Issue:11 Volume:38 Page:2083-2091
ISSN:0253-6269
Container-title:Archives of Pharmacal Research
language:en
Short-container-title:Arch. Pharm. Res.

Author:

Byeon Ji-Yeong,Kim Young-Hoon,Na Han-Sung,Jang Jong-Hwa,Kim Se-Hyung,Lee Yun-Jeong,Bae Jung-Woo,Kim In Su,Jang Choon-Gon,Chung Myeon-Woo,Lee Seok-Yong

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,Drug Discovery,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12272-015-0646-z.pdf

Reference33 articles.

1. Barker, M.J., J.G. Benitez, S. Ternullo, and G.A. Juhl. 2004. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Veterinary and Human Toxicology 46: 130–132.

2. Choi, C.I., J.W. Bae, H.I. Lee, C.G. Jang, U.D. Sohn, and S.Y. Lee. 2012a. Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Chromatography B 885: 103–108.

3. Choi, C.I., C.G. Jang, J.W. Bae, and S.Y. Lee. 2012b. Validation of an analytical LC-MS/MS method in human plasma for the pharmacokinetic study of atomoxetine. Journal of Analytical Chemistry 68: 986–991.

4. Corman, S.L., B.A. Fedutes, and C.M. Culley. 2004. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. American Journal of Health System Pharmacy 61: 2391–2399.

5. Cui, Y.M., C.H. Teng, A.X. Pan, E. Yuen, K.P. Yeo, Y. Zhou, X. Zhao, A.J. Long, M.E. Bangs, and S.D. Wise. 2007. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. British Journal of Clinical Pharmacology 64: 445–449.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine;Archives of Pharmacal Research;2024-04-25

2. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together;Translational Psychiatry;2024-03-19

3. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms;Pharmaceutical Research;2024-03-05

4. Pharmacokinetic Models Scaled Up from Humanized Liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated andN-Demethylated Metabolites in Pediatric Patients Genotyped for CytochromeP450 2D6;Drug Metabolism and Disposition;2023-10-25

5. Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence;European Journal of Clinical Pharmacology;2023-01-16